Palatin Technologies (NYSEAMERICAN:PTN) Stock Rating Reaffirmed by HC Wainwright

HC Wainwright restated their buy rating on shares of Palatin Technologies (NYSEAMERICAN:PTN) in a research note issued to investors on Tuesday, Benzinga reports. They currently have a $17.00 target price on the biopharmaceutical company’s stock. HC Wainwright also issued estimates for Palatin Technologies’ Q1 2025 earnings at ($0.51) EPS, Q2 2025 earnings at ($0.51) EPS, Q3 2025 earnings at ($0.55) EPS, Q4 2025 earnings at ($0.51) EPS and FY2025 earnings at ($2.03) EPS.

Palatin Technologies Stock Performance

Shares of PTN stock opened at $0.83 on Tuesday. Palatin Technologies has a 1 year low of $0.68 and a 1 year high of $5.65. The firm has a market cap of $16.04 million, a PE ratio of -0.33 and a beta of 1.01.

Palatin Technologies (NYSEAMERICAN:PTN) last announced its earnings results on Tuesday, October 1st. The biopharmaceutical company reported ($0.51) earnings per share for the quarter.

Institutional Trading of Palatin Technologies

A hedge fund recently bought a new stake in Palatin Technologies stock. XTX Topco Ltd purchased a new stake in Palatin Technologies, Inc. (NYSEAMERICAN:PTN) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 14,631 shares of the biopharmaceutical company’s stock, valued at approximately $29,000. XTX Topco Ltd owned 0.08% of Palatin Technologies as of its most recent SEC filing. 11.50% of the stock is currently owned by institutional investors and hedge funds.

Palatin Technologies Company Profile

Palatin Technologies, Inc, a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder.